ArticleAmerican journal of translational research2025
Immunoregulatory therapy restores T cell subset balance and reveals risk factors for liver injury in children with infectious mononucleosis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate changes in T-cell subset profiles and factors associated with liver injury in patients with infectious mononucleosis (IM) before and after treatment.
methodsClinical data of 152 children with IM treated at Xijing Hospital from August 2024 were retrospectively analyzed. They were divided into a group with liver injury (n = 78) and a group without liver injury (n = 74). All patients received ganciclovir and pidotimod. T-cell subsets were measured before and after treatment, and factors associated with liver injury were assessed.
resultsAfter treatment, the proportions of CD3
conclusionImmunoregulatory therapy can effectively improve T-cell subset profiles and promote immune recovery in children with IM. Liver injury in IM is associated with age, season of onset, disease duration, fever duration, and disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.